Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group

[1]  M. Bussell.  Improving bone health: addressing the burden through an integrated approach , 2021, Aging Clinical and Experimental Research.

[2]  R. Rizzoli.  Dairy products and bone health , 2021, Aging Clinical and Experimental Research.

[3]  L. Vandenput,et al.  Osteoporosis and fractures in women: the burden of disease , 2021, Climacteric : the journal of the International Menopause Society.

[4]  J. Kanis,et al.  FRAX-based intervention thresholds in eight Eurasian countries: Armenia, Belarus, Georgia, Kazakhstan, the Kyrgyz Republic, Moldova, the Russian Federation, and Uzbekistan , 2021, Archives of Osteoporosis.

[5]  J. Kanis,et al.  SCOPE 2021: a new scorecard for osteoporosis in Europe , 2021, Archives of Osteoporosis.

[6]  M. Javaid.  Efficacy and efficiency of fracture liaison services to reduce the risk of recurrent osteoporotic fractures , 2021, Aging Clinical and Experimental Research.

[7]  M. Paesmans,et al.  Independent External Validation of FRAX and Garvan Fracture Risk Calculators: A Sub‐Study of the FRISBEE Cohort , 2021, JBMR plus.

[8]  M. McClung.  Role of bone-forming agents in the management of osteoporosis , 2021, Aging Clinical and Experimental Research.

[9]  S. Lamb,et al.  Screening and Intervention to Prevent Falls and Fractures in Older People. , 2020, The New England journal of medicine.

[10]  J. Kanis,et al.  Global impact of COVID-19 on non-communicable disease management: descriptive analysis of access to FRAX fracture risk online tool for prevention of osteoporotic fractures , 2020, Osteoporosis International.

[11]  E. McCloskey,et al.  The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study , 2020, Osteoporosis International.

[12]  Erik J. Geiger,et al.  Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. , 2020, The New England journal of medicine.

[13]  Maureen B. Fagan,et al.  A Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries. , 2020, The New England journal of medicine.

[14]  C. Cooper,et al.  Bone densitometry worldwide: a global survey by the ISCD and IOF , 2020, Osteoporosis International.

[15]  P. Elders,et al.  Reply to “Screening for high fracture risk” , 2020, Osteoporosis International.

[16]  J. Reginster,et al.  Fragility fractures in Europe: burden, management and opportunities , 2020, Archives of Osteoporosis.

[17]  T. Peters,et al.  Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study , 2020, Osteoporosis International.

[18]  C. Pari,et al.  Hip fracture systems—European experience , 2020, OTA international : the open access journal of orthopaedic trauma.

[19]  M. Lorentzon,et al.  Association Between Recurrent Fracture Risk and Implementation of Fracture Liaison Services in Four Swedish Hospitals: A Cohort Study , 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  J. Kanis,et al.  A decade of FRAX: how has it changed the management of osteoporosis? , 2020, Aging Clinical and Experimental Research.

[21]  C. Cooper,et al.  General and Specific Considerations as to why Osteoporosis-Related Care Is Often Suboptimal , 2020, Current Osteoporosis Reports.

[22]  T. Peters,et al.  Screening for high hip fracture risk does not impact on falls risk: a post hoc analysis from the SCOOP study , 2020, Osteoporosis International.

[23]  R. Eastell,et al.  Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society , 2019, The Journal of clinical endocrinology and metabolism.

[24]  H. E. van der Horst,et al.  Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis , 2019, Osteoporosis International.

[25]  C. Cooper,et al.  Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures , 2019, Osteoporosis International.

[26]  T. Peters,et al.  Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial , 2019, Osteoporosis International.

[27]  J. Quinzaños-Fresnedo,et al.  Nonpharmacological interventions for osteoporosis treatment: Systematic review of clinical practice guidelines , 2019, Osteoporosis and sarcopenia.

[28]  J. Kanis,et al.  Fracture prediction from self-reported falls in routine clinical practice: a registry-based cohort study , 2019, Osteoporosis International.

[29]  F. Rutters,et al.  The Effect of a Screening and Treatment Program for the Prevention of Fractures in Older Women: A Randomized Pragmatic Trial , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  J. Kanis,et al.  Temporal changes in access to FRAX® in Thailand between 2010 and 2018 , 2019, Archives of Osteoporosis.

[31]  R. Eastell,et al.  Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. , 2019, The Journal of clinical endocrinology and metabolism.

[32]  J. Kanis,et al.  A brief history of FRAX , 2018, Archives of Osteoporosis.

[33]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2018, Osteoporosis International.

[34]  T. Vilaca,et al.  Discordant pattern of peripheral fractures in diabetes: a meta-analysis on the risk of wrist and ankle fractures , 2018, Osteoporosis International.

[35]  M. Gail,et al.  Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening , 2018, Journal of the National Cancer Institute.

[36]  L. Owen,et al.  The cost-effectiveness of public health interventions examined by NICE from 2011 to 2016 , 2018, Journal of public health.

[37]  M. Menon,et al.  Comparing Strategies Targeting Osteoporosis to Prevent Fractures After an Upper Extremity Fracture (C‐STOP Trial): A Randomized Controlled Trial , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[38]  M. Phipps,et al.  Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[39]  Leila C. Kahwati,et al.  Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force , 2018, JAMA.

[40]  C. Cooper,et al.  The Cost‐Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  L. Perdue,et al.  Interventions to Prevent Falls in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force , 2018, JAMA.

[42]  T. Peters,et al.  Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures—A Post Hoc Analysis of the SCOOP Study , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[43]  M. Bech,et al.  Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study , 2018, Osteoporosis International.

[44]  J. Kanis,et al.  FRAX-based intervention and assessment thresholds in seven Latin American countries , 2018, Osteoporosis International.

[45]  Jia-Guo Zhao,et al.  Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults: A Systematic Review and Meta-analysis , 2017, JAMA.

[46]  C. Cooper,et al.  Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial , 2017, The Lancet.

[47]  C. Cooper,et al.  Bisphosphonates in osteoporosis: NICE and easy? , 2017, The Lancet.

[48]  A. Grauer,et al.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis , 2017, The New England journal of medicine.

[49]  Haifeng Guo,et al.  Bone fracture risk in patients with rheumatoid arthritis , 2017, Medicine.

[50]  C. Cooper,et al.  UK clinical guideline for the prevention and treatment of osteoporosis , 2017, Archives of Osteoporosis.

[51]  C. Cooper,et al.  Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting , 2017, Osteoporosis International.

[52]  J. Kanis,et al.  Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures , 2017, Osteoporosis International.

[53]  D. Dempster,et al.  Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[54]  J. Reginster,et al.  The role of calcium supplementation in healthy musculoskeletal ageing , 2017, Osteoporosis International.

[55]  J. Francis,et al.  Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework , 2017, BMC Health Services Research.

[56]  Ran D Balicer,et al.  External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study , 2017, British Medical Journal.

[57]  C. Cooper,et al.  A systematic review of intervention thresholds based on FRAX , 2016, Archives of Osteoporosis.

[58]  C. Weaver,et al.  Erratum and additional analyses re: Calcium plus vitamin D supplementation and the risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation , 2016, Osteoporosis International.

[59]  R. Eastell,et al.  Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study , 2016, British Medical Journal.

[60]  C. Weaver,et al.  Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation , 2015, Osteoporosis International.

[61]  L. Carmona,et al.  The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis , 2015, Annals of the rheumatic diseases.

[62]  B. D. De Stavola,et al.  The Impact of a National Clinician-led Audit Initiative on Care and Mortality after Hip Fracture in England , 2015, Medical care.

[63]  C. Cooper,et al.  FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK , 2015, Osteoporosis International.

[64]  J. Kanis,et al.  Burden of high fracture probability worldwide: secular increases 2010–2040 , 2015, Osteoporosis International.

[65]  A. Saleh,et al.  Systematic review and meta-analysis of the performance of clinical risk assessment instruments for screening for osteoporosis or low bone density , 2015, Osteoporosis International.

[66]  M. Bech,et al.  The Risk-Stratified Osteoporosis Strategy Evaluation study (ROSE): A Randomized Prospective Population-Based Study. Design and Baseline Characteristics , 2015, Calcified Tissue International.

[67]  P. Shekelle,et al.  Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures , 2014, Annals of Internal Medicine.

[68]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis International.

[69]  J A Kanis,et al.  Epidemiology and economic burden of osteoporosis in Switzerland , 2014, Archives of Osteoporosis.

[70]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[71]  C. Cooper,et al.  Osteoporosis in the European Union: a compendium of country-specific reports , 2013, Archives of Osteoporosis.

[72]  C. Cooper,et al.  Osteoporosis in the European Union: medical management, epidemiology and economic burden , 2013, Archives of Osteoporosis.

[73]  R. Rizzoli,et al.  SCOPE: a scorecard for osteoporosis in Europe , 2013, Archives of Osteoporosis.

[74]  J. Kanis,et al.  Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. , 2013, Maturitas.

[75]  Paul D P Pharoah,et al.  Cost effectiveness of the NHS breast screening programme: life table model , 2013, BMJ.

[76]  C. Cooper,et al.  Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle , 2013, Osteoporosis International.

[77]  S. Sen,et al.  Epidemiology of falls and osteoporotic fractures: a systematic review , 2012, ClinicoEconomics and outcomes research : CEOR.

[78]  J. Kanis,et al.  Type 2 diabetes and bone , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[79]  Carol Coupland,et al.  Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study , 2012, BMJ : British Medical Journal.

[80]  T. Peters,et al.  Acceptability of screening to prevent osteoporotic fractures: a qualitative study with older women. , 2012, Family practice.

[81]  C. Cooper,et al.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis , 2012, Osteoporosis International.

[82]  C. Cooper,et al.  A systematic review of hip fracture incidence and probability of fracture worldwide , 2012, Osteoporosis International.

[83]  T. Peters,et al.  A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study , 2012, Osteoporosis International.

[84]  J. Kanis,et al.  Pitfalls in the external validation of FRAX , 2012, Osteoporosis International.

[85]  J. Kanis,et al.  A comparison of case-finding strategies in the UK for the management of hip fractures , 2012, Osteoporosis International.

[86]  P. Dieppe,et al.  Randomized controlled trial of a primary care–based screening program to identify older women with prevalent osteoporotic vertebral fractures: Cohort for skeletal health in Bristol and Avon (COSHIBA) , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[87]  Thomas D Brown,et al.  Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[88]  W. Leslie,et al.  Fracture burden in relation to low bone mineral density and FRAX(®) probability. , 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[89]  C. Gordon,et al.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[90]  S. Boonen,et al.  Coordinator-based systems for secondary prevention in fragility fracture patients , 2011, Osteoporosis International.

[91]  P. Royle,et al.  Denosumab for the prevention of osteoporotic fractures in postmenopausal women. , 2011, Health technology assessment.

[92]  S. Cummings,et al.  Secular trends in the incidence of hip and other osteoporotic fractures , 2011, Osteoporosis International.

[93]  Virginia A. Moyer,et al.  Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement , 2011, Annals of Internal Medicine.

[94]  David A Hanley,et al.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary , 2010, Canadian Medical Association Journal.

[95]  Bonnie Spring,et al.  Measuring smoking-related preoccupation and compulsive drive: evaluation of the obsessive compulsive smoking scale , 2010, Psychopharmacology.

[96]  Gary S Collins,et al.  An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study , 2010, BMJ : British Medical Journal.

[97]  D. Torgerson,et al.  Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk , 2010, Osteoporosis International.

[98]  J. Hippisley-Cox,et al.  Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores , 2009, BMJ : British Medical Journal.

[99]  J. Kanis,et al.  Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study , 2009, Osteoporosis International.

[100]  D. Marsh,et al.  Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. , 2009, Maturitas.

[101]  S. Berry,et al.  Falls: Epidemiology, pathophysiology, and relationship to fracture , 2008, Current osteoporosis reports.

[102]  L. Melton,et al.  A reference standard for the description of osteoporosis. , 2008, Bone.

[103]  F. McAlister,et al.  Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial , 2008, Canadian Medical Association Journal.

[104]  O. Johnell,et al.  FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.

[105]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[106]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[107]  G. Anderson,et al.  Predicting risk of breast cancer in postmenopausal women by hormone receptor status. , 2007, Journal of the National Cancer Institute.

[108]  S. Silverman,et al.  Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[109]  W. Willett,et al.  Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. , 2007, American journal of epidemiology.

[110]  S. Cummings,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[111]  J. Eisman,et al.  Risk factors for fracture in nonosteoporotic men and women. , 2007, The Journal of clinical endocrinology and metabolism.

[112]  Mark Stevenson,et al.  Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. , 2007, Health technology assessment.

[113]  Jacques P. Brown,et al.  The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.

[114]  John Brazier,et al.  Clodronate Reduces the Incidence of Fractures in Community‐Dwelling Elderly Women Unselected for Osteoporosis: Results of a Double‐Blind, Placebo‐Controlled Randomized Study , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[115]  O. Johnell,et al.  An estimate of the worldwide prevalence and disability associated with osteoporotic fractures , 2006, Osteoporosis International.

[116]  K. Malterud,et al.  Making the invisible body visible. Bone scans, osteoporosis and women's bodily experiences. , 2006, Social science & medicine.

[117]  A. Silman,et al.  Predictive Value of BMD for Hip and Other Fractures , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[118]  Olof Johnell,et al.  Alcohol intake as a risk factor for fracture , 2005, Osteoporosis International.

[119]  H. Kroger,et al.  Body mass index as a predictor of fracture risk: A meta-analysis , 2005, Osteoporosis International.

[120]  O. Johnell,et al.  Requirements for DXA for the management of osteoporosis in Europe , 2005, Osteoporosis International.

[121]  H. Kroger,et al.  Smoking and fracture risk: a meta-analysis , 2005, Osteoporosis International.

[122]  O Johnell,et al.  A family history of fracture and fracture risk: a meta-analysis. , 2004, Bone.

[123]  B. Rowe,et al.  A Controlled Trial To Increase Detection and Treatment of Osteoporosis in Older Patients with a Wrist Fracture , 2004, Annals of Internal Medicine.

[124]  O Johnell,et al.  A meta-analysis of previous fracture and subsequent fracture risk. , 2004, Bone.

[125]  Olof Johnell,et al.  A Meta‐Analysis of Prior Corticosteroid Use and Fracture Risk , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[126]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[127]  A. LaCroix,et al.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.

[128]  O. Johnell,et al.  The components of excess mortality after hip fracture. , 2003, Bone.

[129]  W. Willett,et al.  Walking and leisure-time activity and risk of hip fracture in postmenopausal women. , 2002, JAMA.

[130]  C. Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[131]  E. Thomas,et al.  `I'd rather go and know': women's understanding and experience of DEXA scanning for osteoporosis , 2002, Health expectations : an international journal of public participation in health care and health policy.

[132]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[133]  D. Torgerson,et al.  Randomized trial of osteoporosis screening. Use of hormone replacement therapy and quality-of-life results. , 1997, Archives of internal medicine.

[134]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[135]  W M O'Fallon,et al.  Determinants of Reduced Survival Following Hip Fractures in Men , 1995, Clinical orthopaedics and related research.

[136]  M. Parker,et al.  Mortality and morbidity after hip fractures. , 1993, BMJ.

[137]  C. Christiansen,et al.  Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. , 1993, The American journal of medicine.

[138]  Claus Christiansen,et al.  Diagnosis of Osteoporosis , 1992, Southern medical journal.

[139]  S. Cummings,et al.  A hypothesis: the causes of hip fractures. , 1989, Journal of gerontology.

[140]  H. Bischoff-Ferrari,et al.  MANAGEMENT OF ENDOCRINE DISEASE: Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency; a position statement of the European Calcified Tissue Society. , 2019, European journal of endocrinology.

[141]  J. Kanis,et al.  Access to fracture risk assessment by FRAX and linked National Osteoporosis Guideline Group (NOGG) guidance in the UK—an analysis of anonymous website activity , 2016, Osteoporosis International.

[142]  E. McCloskey,et al.  A BMD threshold for treatment efficacy in osteoporosis? A need to consider the whole evidence base , 2015, Osteoporosis International.

[143]  L. Lix,et al.  Comparison between various fracture risk assessment tools , 2013, Osteoporosis International.

[144]  A. Slater,et al.  Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60–69 years , 2010, Applied health economics and health policy.

[145]  National Institute for Health and Clinical Excellence , 2010 .

[146]  Sarah E Lamb,et al.  Interventions for preventing falls in older people living in the community. , 2009, The Cochrane database of systematic reviews.

[147]  A. Berg.  Screening for osteoporosis in postmenopausal women , 2003 .

[148]  O. Johnell,et al.  Cost-Effectiveness of Preventing Hip Fracture in the General Female Population , 2001, Osteoporosis International.

[149]  O. Johnell,et al.  The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds , 2001, Osteoporosis International.

[150]  H. Genant,et al.  Radiation exposure in bone mineral density assessment. , 1999, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[151]  T. Kennedy.  The prevention of falls in later life. A report of the Kellogg International Work Group on the Prevention of Falls by the Elderly. , 1987, Danish medical bulletin.

[152]  Ja Wilson,et al.  Principles and practice of screening for disease , 1968 .